Data Safety Monitoring Board Sample Clauses

Data Safety Monitoring Board. A Data Safety Monitoring Board (DSMB) will be formed according to Omnicare CR’s operating procedures and will be solely responsible for evaluating the interim results of the study. One (1) organizational meeting and one (1) interim analysis evaluation meeting are planned. Omnicare CR and Sponsor will jointly develop guidelines for membership of the DSMB, and for conduct of DSMB meeting to be documented in the DSMB Charter. The DSMB members will be recruited by Omnicare/Sponsor. Members of the DSMB will neither have previous involvement with Sponsor’s studies in this area, nor be currently involved in clinical trials of competing therapies. The DSMB will have a written charter that will be produced by a Project Director which will define the responsibilities and will maintain records of all meetings. The written charter will also include a statistical appendix that will document the requirements and guidelines for analyzing and interpreting the interim safety results. Omnicare CR’s biometrics team will prepare mock data displays specific to the DSMB charter. A senior statistician, otherwise unrelated to the study, will be responsible for the development of the data displays defined by the DSMB to ensure interim data accuracy and summaries are produced. These data displays will be programmed and validated by biometrics staff. The validation will be performed through a combination of individual patient data review and independent programming. When the blind is ready to be broken, the DSMB statistician will perform the final run of the DSMB data displays and prepare for the DSMB. For each DSMB meeting, the database will be extracted and the data listings and summary tables will be rerun. If the DSMB requests data clarification or further information, Omnicare CR will re-extract the data and rerun the listings and tables on the new data. **** Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
Data Safety Monitoring Board. An independent DSMB will be established and will review the safety of study treatment and any SAEs that occur during the study. Details on how the DSMB will review safety and response data are provided in the DSMB Charter. The DSMB will be composed of at least 2 oncologists (at least one of whom specializes in CRC) and a statistician. Following their initial meeting, the DSMB will meet approximately every 6 months to review clinical data and provide recommendations to the Sponsor on whether the study should continue. The DSMB may also meet more frequently, if needed.
Sample 1
Data Safety Monitoring Board. An independent Data Safety Monitoring Board (DSMB) will be chartered to review safety data to make trial conduct recommendations. The DSMB will review safety data in an interim analysis during the Phase 2 portion of the study. For this interim analysis, the DSMB will review safety data after 20 Phase 2 subjects have been treated with KTE-X19 and had the opportunity to be followed for 30 days after the KTE-X19 infusion. During Phase 2, Kite Pharma or delegate will submit SAEs or suspected unexpected serious adverse reactions (SUSARs) to the DSMB chair for risk benefit analysis. The DSMB Chair will review reported SAEs at least monthly and SUSARs as soon as received. .
Sample 1
Data Safety Monitoring Board. An independent Data Safety Monitoring Board (DSMB) will monitor the trial. The DSMB will comprise of medical professionals with expertise in XXXX and clinical trials and are external to the Sponsor. The DSMB will meet periodically or as needed to review accumulating safety data and any available PK data collected throughout the trial. Safety and available PK data will be reviewed by the DSMB prior to proceeding with the next higher dose cohort. The DSMB will review safety data when at least six (6) subjects in Cohort A (CRV431 75 mg) and at least three (3) subjects in Cohort B (matching placebo) have reached 28 days of dosing, as described in Section 12.3.1. The DSMB will also review the Day 28 safety data from the remaining subjects to confirm there are no changes to the prior safety assessment. The roles and responsibilities will be further defined in a Charter.
Sample 1
Data Safety Monitoring Board. Sponsor understands that the Data Safety Monitoring is a requirement of this study and the Data Safety Monitoring Board (DSMB) services provided by Sponsor must meet the requirements of the FDA policy (reference: xxxxx://xxx.xxx.xxx/OHRMS/DOCKETS/98fr/01d-0489-gdl0003.pdf). DSMB Members will not be Staff of the Sponsor or Institution. Additionally, Sponsor will allow Institution's Principal Investigator to review and approve DSMB Committee Members prior to their appointment to the Committee."
Sample 1
Data Safety Monitoring Board. An independent DSMB will review safety and/or efficacy data 4 times during this study. The DSMB will first meet to review safety data when 10 subjects in Cohort 1 have been enrolled and treated with anti-CD19 CAR T cells and followed for 30 days. The DSMB will meet for the second time to review both safety and efficacy data after 20 subjects in Cohort 1 have been treated with anti-CD19 CAR T cells and have had the opportunity to complete the 3-month disease assessment. The DSMB will meet for the third time to review both safety and efficacy data after 10 subjects in Cohort 2 have been treated with KTE-X19 and have had the opportunity to be followed for 30 days. The DSMB will meet for the fourth time after 44 subjects in Cohort 1 have been treated with anti‑CD19 CAR T cells and have had opportunity to be followed for 30 days after the IP infusion. The DSMB will be chartered to make trial conduct recommendations based on an analysis of risk vs benefit. The DSMB may meet more often as needed. At the time of expedited reporting of suspected unexpected serious adverse reactions (SUSARs) to health authorities, Kite (or designee) will concurrently submit these reports to the DSMB chair. The DSMB chair will also review SAE narrative reports monthly. Finally, the DSMB or Kite may request additional analyses of safety data if a safety concern arises during the course of the trial.
Sample 1
Data Safety Monitoring Board. ‌ A Data Safety Monitoring Board (DSMB) will monitor the progress of the PGP-UK, including the risks to study participants. Although the PGP-UK will attempt to inform you of additional risks identified by the DSMB, including through updates to the study website, the DSMB will not be able to monitor all of the risks of participation in this study, and it may not be able to advise you or the PGP-UK of those risks that it monitors or identifies.
Sample 1
AutoNDA by SimpleDocs
Data Safety Monitoring Board. An independent Data Safety Monitoring Board (DSMB) will review unblinded safety data throughout the study and make recommendations as appropriate. The DSMB will begin quarterly data reviews approximately 3 months after the first patient is enrolled and continue through the last dose of the last patient enrolled. The DSMB will consist of external experts supported by an independent statistical group. The independent statistical group will prepare unblinded analyses for the DSMB and will not have a role in the statistical analysis plan (SAP) after the study has started enrolling patients. A separate, blinded statistical group (i.e., not associated with the DSMB) will be responsible for producing and finalizing the SAP and executing final data analysis of the study. The DSMB will be governed by a charter that will describe the following: • Roles and responsibilities of the DSMB members and the independent statistical group • Meeting format and frequency • Communication channels between the DSMB, the independent statistical group, the Sponsor, and the blinded study statisticians • Voting process and requirements (e.g., requirement of consensus for issuance of a termination recommendation) • Provisions governing conflict of interest and confidentiality • Process for interim analysis of efficacy, including the alpha spending function Briefly, the DSMB will review the progress of the study and the accumulating unblinded data while the study is ongoing. The DSMB will make recommendations to Sponsor representatives following each meeting. The DSMB may recommend that the study continue as is, be modified to protect patient safety, or be terminated. However, investigators, and not the DSMB, will make intra-patient dose-escalation decisions at the Week 4 visit for each patient and may choose to decrease the patient’s dose (to one-half of the prior dose).‌‌‌
Sample 1

Related to Data Safety Monitoring Board

  • COUNTY’S QUALITY ASSURANCE PLAN The County or its agent will evaluate the Contractor’s performance under this Contract on not less than an annual basis. Such evaluation will include assessing the Contractor’s compliance with all Contract terms and conditions and performance standards. Contractor deficiencies which the County determines are severe or continuing and that may place performance of the Contract in jeopardy if not corrected will be reported to the Board of Supervisors. The report will include improvement/corrective action measures taken by the County and the Contractor. If improvement does not occur consistent with the corrective action measures, the County may terminate this Contract or impose other penalties as specified in this Contract.

  • Quality Assurance Program An employee shall be entitled to leave of absence without loss of earnings from her or his regularly scheduled working hours for the purpose of writing examinations required by the College of Nurses of Ontario arising out of the Quality Assurance Program.

  • Quality Assurance/Quality Control Contractor shall establish and maintain a quality assurance/quality control program which shall include procedures for continuous control of all construction and comprehensive inspection and testing of all items of Work, including any Work performed by Subcontractors, so as to ensure complete conformance to the Contract with respect to materials, workmanship, construction, finish, functional performance, and identification. The program established by Contractor shall comply with any quality assurance/quality control requirements incorporated in the Contract.

  • Accident Prevention Health and Safety Committee (a) The Employer and the Union agree that they mutually desire to maintain standards of safety and health in the workplace in order to prevent accidents, injury and illness. (b) Recognizing its responsibilities under the applicable legislation, the Employer agrees to accept as a member of its Accident Prevention – Health & Safety Committee at least three (3) representatives, one from each base, selected or appointed by the Union from amongst bargaining unit employees. At any time where a vote is required, an equal number of representatives from each side shall be entitled to vote. (c) Such Committee shall identify potential dangers and hazards, institute means of improving health and safety programs and recommend actions to be taken to improve conditions related to safety and health. (d) The Employee agrees to co-operate reasonably in providing necessary information to enable the Committee to fulfill its functions. (e) Meetings shall be held quarterly or more frequently at the call of the Chair if required. The Committee shall maintain minutes of all meetings and make the same available for review. (f) Any representative appointed or select in accordance with (b) hereof shall serve a term of one (1) calendar year from the date of appointment which may be renewed for further periods of one (1) year. The Union will encourage its representative(s) to serve at least one (1) year. Time off for such representative(s) to attend meetings of the Accident Prevention – Health & Safety Committee in accordance with the foregoing shall be granted and time so spent attending such meetings shall be deemed to be work time for which the representative(s) shall be paid by the Employer at his regular or premium rate as may be applicable. (g) The Union agrees to endeavour to obtain the full co-operation of its membership in the observation of all safety rules and practices. (h) Pregnant employees may request to be transferred from their current duties if, in the professional opinion of the employee’s physician, the pregnancy may be at risk. If such a transfer is not feasible, the pregnant employee, if she so requests, will be granted an unpaid leave of absence before commencement of the maternity leave referred to in Article 16.04

  • Health & Safety Committee The Employer agrees to establish a Health & Safety Committee for all employees of the company under the auspices of the Occupational Health and Safety Act (OHSA). The Committee shall be made up of an equal number (not less than one each) of non-bargaining unit and bargaining unit persons who have completed their probationary period. The Union has the right to appoint the members representing the bargaining unit. The Committee shall keep minutes of its meetings and post them in the shop. One copy will be forwarded to the Union office.

  • Evaluation, Testing, and Monitoring 1. The System Agency may review, test, evaluate and monitor Grantee’s Products and services, as well as associated documentation and technical support for compliance with the Accessibility Standards. Review, testing, evaluation and monitoring may be conducted before and after the award of a contract. Testing and monitoring may include user acceptance testing. Neither the review, testing (including acceptance testing), evaluation or monitoring of any Product or service, nor the absence of review, testing, evaluation or monitoring, will result in a waiver of the State’s right to contest the Grantee’s assertion of compliance with the Accessibility Standards. 2. Grantee agrees to cooperate fully and provide the System Agency and its representatives timely access to Products, records, and other items and information needed to conduct such review, evaluation, testing, and monitoring.

  • Project Management Plan 3.2.1 Developer is responsible for all quality assurance and quality control activities necessary to manage the Work, including the Utility Adjustment Work. Developer shall undertake all aspects of quality assurance and quality control for the Project and Work in accordance with the approved Project Management Plan, Good Industry Practice and applicable Law. 3.2.2 Developer shall develop the Project Management Plan and its component parts, plans and other documentation in accordance with the requirements set forth in Section 1.5.2.5

  • PERFORMANCE MANAGEMENT SYSTEM 6.1 The Performance Plan (Annexure A) to this Agreement sets out – 6.1.1 The standards and procedures for evaluating the Employee’s performance; and 6.1.2 The intervals for the evaluation of the Employee’s performance. 6.2 Despite the establishment of agreed intervals for evaluation, the Employer may in addition review the Employee’s performance at any stage while the contract of employment remains in force; 6.3 Personal growth and development needs identified during any performance review discussion must be documented in a Personal Development Plan as well as the actions agreed to and implementation must take place within set time frames; 6.4 The Employee’s performance will be measured in terms of contributions to the goals and strategies set out in the Employer’s Integrated Development Plan (IDP) as described in 6.6 – 6.12 below; 6.5 The Employee will submit quarterly performance reports (SDBIP) and a comprehensive annual performance report at least one week prior to the performance assessment meetings to the Evaluation Panel Chairperson for distribution to the panel members for preparation purposes; 6.6 Assessment of the achievement of results as outlined in the performance plan: 6.6.1 Each KPI or group of KPIs shall be assessed according to the extent to which the specified standards or performance targets have been met and with due regard to ad-hoc tasks that had to be performed under the KPI, and the score of the employer will be given to and explained to the Employee during the assessment interview. 6.6.2 A rating on the five-point scale shall be provided for each KPI or group of KPIs which will then be multiplied by the weighting to calculate the final score; 6.6.3 The Employee will submit his self-evaluation to the Employer prior to the formal assessment; 6.6.4 In the instance where the employee could not perform due to reasons outside the control of the employer and employee, the KPI will not be considered during the evaluation. The employee should provide sufficient evidence in such instances; and 6.6.5 An overall score will be calculated based on the total of the individual scores calculated above.

  • Joint Safety Committee (a) The Union and the Company shall cooperate in selecting one or more Safety Committees, which will meet at least once a month to consider all safety and occupational health problems. (b) The local Joint Safety Committee shall consist of equal representation from Company and Union. This Committee shall meet at least once a month to consider all safety and occupational health problems.

  • Safety Boots Each employee, after 3 months’ continuous service, will be reimbursed (on production of a receipt), the cost of one pair of safety boots (approved by the employer), in each year, to a maximum of $110.00. All protective clothing such as wet weather jackets, safety helmets, welding jackets, welding xxxxxxx, welding gauntlets, rubber boots, etc, (which remain the property of the Company), will be supplied on all occasions deemed necessary.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!